Recent Omnicell share moves and business snapshot

Omnicell (OMCL) has drawn fresh attention after recent share price moves, with the stock last closing at US$43.05. Investors are weighing this against the company’s current earnings profile and recent share performance.

Over the past month the stock return is 7.28%, while the past 3 months are broadly flat with a slight decline of 0.12%. The 1 year total return stands at 45.37% and the year to date performance reflects a decline of 4.63%.

The recent 1 month share price return of 7.28% comes after a much stronger 1 year total shareholder return of 45.37%. However, the 3 and 5 year total shareholder returns have been weak, which suggests momentum has only recently improved as investors reassess Omnicell’s earnings profile and risk.

If Omnicell’s move has you looking beyond a single stock, this is a good moment to broaden your watchlist with the 40 healthcare AI stocks

Omnicell now trades at a discount to both some intrinsic value estimates and analyst targets after a strong 1 year rebound. Is the market’s caution still warranted, or has the recent reset gone too far on valuation?

Most Popular Narrative: 29.8% Undervalued

Against Omnicell’s last close of $43.05, the most widely followed narrative puts fair value at about $61.29. This frames the current discount and the earnings story behind it.

The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.

Curious how Omnicell’s fair value leans so far above today’s share price? The narrative leans heavily on a shift in margins, mix and earnings power. The numbers behind those assumptions are punchy. The full breakdown shows exactly how revenue, profitability and future valuation multiples are stitched together to support that $61.29 figure.

Result: Fair Value of $61.29 (UNDERVALUED)

However, Omnicell’s story still hinges on tariffs and hospital capital budgets, which could pressure margins and delay large automation projects if conditions worsen.

Another view on Omnicell’s valuation

While the analyst narrative anchors on a fair value of $61.29, Omnicell’s current P/E of 95.8x tells a tougher story. That multiple sits above the US Medical Equipment industry at 28x and peers at 91.4x, and is also far above a fair ratio of 37.3x. Is the stock’s earnings profile strong enough to justify staying this far above those markers?

For a closer look at how these P/E gaps might affect potential valuation risk or opportunity, take a look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mixed tone of this Omnicell review might leave you with as many questions as answers, which is a healthy place to be. Treat this as a prompt to move quickly, review the latest data, and stress test which parts of the story you agree with. Then see how those views line up with the 3 key rewards

Looking for more Omnicell investment ideas?

If Omnicell has caught your attention, do not stop here. Broaden your opportunity set now by checking focused stock ideas built from the latest data.

• Target higher quality opportunities by reviewing the 49 high quality undervalued stocks that combine attractive pricing with stronger fundamentals.
• Strengthen downside protection by scanning the 83 resilient stocks with low risk scores that screen for resilience and more robust risk scores.
• Get ahead of the crowd by researching the screener containing 20 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.